Condition Directory

Obesity clinical trials

Directory of U.S. ClinicalTrials.gov public records for Obesity. Browse Obesity recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 30, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

6025

Shown on this page

Current sort

How Obesity studies are organized in the registry

Obesity research spreads across several neighboring registry terms — “overweight,” “weight loss,” and “metabolic syndrome” all label closely related studies — so checking more than one term gives a fuller picture. The portfolio includes many behavioral and lifestyle studies alongside drug trials, which makes the study-type filter (interventional vs. observational) more informative than usual.

Terms that often appear in related listings

weight loss overweight metabolic syndrome bariatric

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 169–180 of 6,025 matching trials for Obesity.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Obesity or Overweight
Interventions: Placebo, Enicepatide; Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 44
States / cities: Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 37 more

Conditions: Obesity, Overweight
Interventions: BI 3034701, Placebo matching BI 3034701; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • West Hills, California • Miami, Florida + 16 more

Conditions: Apnea, Sleep Disorders, Overweight and/or Obesity
Interventions: Berobenatide, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Cullman, Alabama • Riverside, California • Bradenton, Florida + 3 more

Conditions: Obese But Otherwise Healthy Participants
Interventions: CRB-913, Placebo; Drug
Lead sponsor: Corbus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 15
States / cities: Birmingham, Alabama • Chandler, Arizona • Rancho Cucamonga, California + 12 more

Conditions: Type 2 Diabetes
Interventions: LY3457263, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Santa Ana, California • Ocala, Florida + 21 more

Conditions: Obese Individuals, Central Adiposity
Interventions: Beetroot Juice - Active + Exercise, Beetroot juice placebo + Exercise, Beetroot Juice - Active + No exercise, Beetroot juice placebo+ No exercise; Dietary Supplement
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Pregnancies at Increased Risk for Excessive Gestational Weight Gain, Ecological Momentary Assessment and Intervention, Continuous Glucose Monitor
Interventions: Continuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancy; Behavioral
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Discrimination, Racial, Social Isolation, Stress
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 266 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions: Macupatide, Eloralintide, Macupatide Placebo, Eloralintide Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 26
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more

Conditions: Obesity and Overweight
Interventions: Diet containing 80% ultra processed foods, Diet containing 20% ultra processed foods; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 25 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Metabolic Disorders, Physical Inactivity, Vascular Disease Risk
Interventions: reduced physical activity; Other
Lead sponsor: Miami University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Oxford, Ohio

Conditions: Obesity, Food Addiction
Interventions: Probiotic, Placebo; Dietary Supplement
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

About this Obesity clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Obesity as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Obesity.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Obesity clinical trials

How Obesity studies are organized in the registry

Filter and sort this condition

Live official records

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Post-exercise Blood Pressure With Inorganic Nitrate

Continuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancies - The GEM Study

Discrimination and the Brain-Gut-Microbiome (BGM) Axis

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Effects of Ultra Processed Food on Intestinal Energy Harvest

Interactive Roles of Cardiorespiratory Fitness and Adiposity on Glucose and Vascular Control After Physical Inactivity

Probiotic Intervention Study

About this Obesity clinical trials directory page